Financial Disclosure

Tokyo – – September 28, 2026 -- TOYO Co., Ltd. (Nasdaq: TOYO; OTC: TOYWF) said it expects positive EBITDA for the second half of 2026 despite withholding specific revenue and net income guidance due to unresolved U.S. trade actions affecting its solar cell shipments.

Unresolved US Customs Probe Clouds Financial Visibility

The Tokyo-based solar manufacturer cited a pending U.S. Customs and Border Protection examination of its solar cell shipments as a key source of uncertainty for its second-half performance. TOYO said it will not issue quarterly guidance or specific financial metrics until greater regulatory clarity emerges.

Countervailing Duty Investigation Adds to Policy Risk

Active countervailing duty investigation proceedings compound the regulatory overhang facing the company, according to the statement. TOYO did not disclose a timeline for resolution of either the CBP examination or the CVD case.

Piscataway, N.J. – September 28, 2026 -- Sampled has secured a five-year contract worth up to $27.1 million from the Department of Veterans Affairs to provide genomics analyses for the Million Veteran Program (MVP), one of the world's largest research initiatives of its kind.

MVP has enrolled more than one million veterans since its 2011 launch

The program studies how molecular factors, lifestyle, and service-related experiences drive elevated veteran health risks, including PTSD, cardiovascular disease, and cancer. Published MVP findings have already advanced understanding of PTSD, artery disease, suicide risk, stroke, and substance use.

September 28, 2026 – Kuwait City – -- HONOR grew smartphone shipments 35% year on year in the Middle East during the first half of 2026, even as the overall regional market contracted 13%, according to Omdia data cited by the company. The brand was the only major vendor in the region to post growth in the period, moving into second place in the market after posting 73% growth in the first quarter alone.

HONOR captures 24% share of the $300-500 price band

The gains were concentrated in the mid-to-high-end segment. HONOR took a 24% share of the $300-500 price band in the first quarter of 2026, up 130% year on year, narrowing the gap with Samsung in that category. The HONOR X9d, positioned on durability and battery life, became a top seller in both Saudi Arabia and the UAE, while the HONOR 600 Series delivered double-digit growth in what the company calls the accessible flagship segment.

Friendswood, Texas – September 28, 2026 -- Castle Biosciences, Inc. (Nasdaq: CSTL) said a new peer-reviewed study found its TissueCypher Barrett's Esophagus Test prompted clinicians to change management recommendations in 90% of cases involving patients with non-dysplastic Barrett's esophagus (NDBE).

The case series, published in Foregut: The Journal of the American Foregut Society, evaluated 30 NDBE patients tested as part of clinical care at Keck Medical Center of the University of Southern California (USC).

Test reclassifies risk within a population considered uniformly low-risk

TissueCypher classified 17% of the 30 patients as intermediate or high risk for progression to high-grade dysplasia or esophageal adenocarcinoma within five years, while 83% were confirmed low risk. All patients had received the same NDBE diagnosis prior to testing.

New York – September 28, 2026 -- Brixmor Property Group Inc. (NYSE: BRX) and Everview Partners have entered definitive agreements to acquire Slate Grocery REIT in a transaction valued at $2.34 billion, splitting the portfolio between a wholly owned Brixmor acquisition and a newly formed joint venture backed by a subsidiary of the Abu Dhabi Investment Authority.

Brixmor takes wholly owned stake in 23 centers for $636 million

Brixmor will directly acquire 23 grocery-anchored shopping centers totaling approximately three million square feet for $636 million, gaining a 100% interest in 22 assets and a 50% stake in one. The portfolio is 96% leased and sits entirely within Brixmor's existing footprint, concentrated in Florida, Georgia and the Carolinas, with anchors including Publix, Harris Teeter and Kroger.

Toronto – September 28, 2026 -- Sixty Degree Capital (SDC) saw five portfolio companies complete initial public offerings in 2026, including the largest IPO in history and the largest biotech IPO on record. SpaceX, Parabilis Medicines, Cerebras, HawkEye 360 and Lime each began trading on U.S. exchanges between May and July, while GrubMarket has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission.

SpaceX offering reaches approximately US$75 billion, the largest IPO ever recorded

SpaceX's public listing totaled roughly US$75 billion, according to the Toronto-based venture capital firm, marking the largest IPO in history. The offering anchors a wave of 2026 public-market exits across SDC's technology and healthcare portfolio.

Chicago – September 28, 2026 -- GTCR has closed its acquisition of Tactacam, a cellular-connected camera provider serving more than one million subscribers, buying the company from Bertram Capital and its founders in a deal with undisclosed terms.

Founders retain ownership as CEO stays on to lead the business

Jeff Peel, Tactacam's CEO and co-founder, will continue leading the Company and retain significant ownership alongside co-founder Ben Thorud. Peel said the partnership with GTCR will support continued investment in the Reveal and Defend product lines while preserving the company's customer-focused approach.

Shanghai – – September 28, 2026 -- MOYOM Biotech, a Chinese developer of regenerative aesthetic biomaterials, has secured a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital, to fund international expansion of its flagship CaHA-based implant brand Aphranel®.

Cathay Capital Fund Backed by L'Oréal Targets Beauty and Skin Science Innovation

The investment vehicle was jointly established by Cathay Capital, L'Oréal and the Shanghai Jing'an District Government. Cathay Capital's broader portfolio includes Moonshot AI (Kimi), autonomous driving firm Momenta, U.S. fintech Chime, digital asset platform Ledger, delivery platform Glovo and AI biotech company Owkin.

New York – – September 28, 2026 -- Infrastructure Capital Advisors, LLC has increased monthly distributions across four exchange-traded funds, with its newest fund, the Nasdaq Option Income ETF (QVOL), raising its payout by $0.05 to $1.09 per share.

QVOL lifts monthly distribution to $1.09 per share, an annualized $13.08

The increase moves QVOL's per-share payout from $1.04 to $1.09, translating to $13.08 on an annualized basis. The fund targets an annualized distribution rate of between 12% and 15%, generated through call-option premiums and dividends from its equity holdings tied to the Nasdaq. Infrastructure Capital cautioned that the target range does not equate to a guaranteed yield or total return, and that distributions may include a portion classified as return of capital.

Tokyo – September 28, 2026 -- SOLA Biosciences Japan GK has secured a grant of approximately 6 billion yen over five years from Japan's Agency for Medical Research and Development (AMED) to advance SOL-257, a gene therapy candidate targeting the TDP-43 protein implicated in amyotrophic lateral sclerosis (ALS). The award, granted under AMED's Strengthening Program for Pharmaceutical Startup Ecosystem, was announced June 5, 2026, and positions SOLA Japan as the company's central development hub for the program.

AMED grant targets a pathology present in 97% of ALS cases

SOL-257 is designed to restore the structure and function of misfolded TDP-43, a protein that becomes mislocalized and aggregated in motor neurons in roughly 97% of ALS cases, according to SOLA. The company describes SOL-257 as a potentially first-in-class, disease-modifying gene therapy built on its proprietary JUMP70 platform.